Retrospective Review of Patients With Myasthenia Gravis Switched From Plasma Exchange Therapy to Efgartigimod Treatment
Source : https://pubmed.ncbi.nlm.nih.gov/38284651/
In this series, efgartigimod appeared effective and well tolerated in patients switched from TPE.
After receiving efgartigimod infusions, 5 of 7 patients demonstrated improvement in Myasthenia Gravis Foundation of America–postintervention status.
Correlation of Fatigue on Walking Ability in Myasthenia Gravis Patients: a Cross-Sectional Study
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10783269/
Myasthenia gravis (MG) is a neuromuscular junction autoimmune disease characterised of intermittent muscle weakness that increases with activity and recovers with rest.Analysing the correlation of fatigue on walking ability in...
There is no significant correlation between fatigue and walking ability, including comfortable walking speed, maximal walking speed, and natural cadence.
Evaluation of Medication Exposure on Exacerbation of Disease in Patients With Myasthenia Gravis
Source : https://pubmed.ncbi.nlm.nih.gov/38235027/
Of the medications reported to potentially worsen MG, intravenous labetalol and intravenous magnesium were the 2 agents associated with myasthenic exacerbations with a higher incidence in patients harboring additional risk...
Of the medications reported to potentially worsen MG, intravenous labetalol and intravenous magnesium were the 2 agents associated with myasthenic exacerbations with a higher incidence in patients harboring additional risk factors.
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Source : https://pubmed.ncbi.nlm.nih.gov/38165333/
This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual dose but demonstrated a significant dose...
Nipocalimab was generally safe, well tolerated, and showed evidence of dose-dependent reduction in MG-ADL scores after nearly 2 months in this phase 2 study.
Serum Amyloid A Facilitates Expansion of CD4+ T Cell and CD19+ B Cell Subsets Implicated in the Severity of Myasthenia Gravis Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38214332/
Serum amyloid A (SAA) is a clinically useful inflammatory marker involved in the pathogenesis of autoimmune diseases. This study aimed to explore the SAA levels in a cohort of patients...
Serum amyloid A levels in patients with new-onset myasthenia gravis were higher than those in controls and were positively correlated with QMG score, MGFA classification, plasmablast cells, and IL-6/-17 levels.